Related references
Note: Only part of the references are listed.Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition
Stephan Seitz et al.
ANTI-CANCER DRUGS (2009)
Development of an Oxime Bond Containing Daunorubicin-Gonadotropin-Releasing Hormone-III Conjugate as a Potential Anticancer Drug
Ildiko Szabo et al.
BIOCONJUGATE CHEMISTRY (2009)
99mTc-HYNIC-TOC Scintigraphy Is Superior to 131I-MIBG Imaging in the Evaluation of Extraadrenal Pheochromocytoma
Libo Chen et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Luteinizing Hormone-Releasing Hormone Receptor-Targeted Chemotherapy Using AN-152
Guenter Emons et al.
NEUROENDOCRINOLOGY (2009)
Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162
Andrea Treszl et al.
PEPTIDES (2009)
99mTc-HYNIC octreotide in neuroblastoma
Juan P. Gambini et al.
ANNALS OF NUCLEAR MEDICINE (2008)
Therapy of experimental hepatic cancers with cytotic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin
Karoly Szepeshazi et al.
ANTI-CANCER DRUGS (2008)
Design, Synthesis, and In Vitro Activity of Novel Drug Delivery Systems Containing Tuftsin Derivatives and Methotrexate
Katalin B. Bai et al.
BIOCONJUGATE CHEMISTRY (2008)
closo-borane conjugated regulatory peptides retain high biological affinity:: Synthesis of closo-borane conjugated Tyr3-octreotate derivatives for BNCT
Thomas Betzel et al.
BIOCONJUGATE CHEMISTRY (2008)
Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency
Margret Schottelius et al.
BIOCONJUGATE CHEMISTRY (2008)
Peptide-based radiopharmaceuticals and cytotoxic conjugates: Potential tools against cancer
S. M. Okarvi
CANCER TREATMENT REVIEWS (2008)
New Derivatives of GnRH as Potential Anticancer Therapeutic Agents
Gabor Mezo et al.
CURRENT MEDICINAL CHEMISTRY (2008)
Mammalian type I gonadotropin-releasing hormone receptors undergo slow, constitutive, agonist-independent internalization
Adam J. Pawson et al.
ENDOCRINOLOGY (2008)
Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice
Hongchang Shen et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
New approaches to the therapy of various tumors based on peptide analogues
A. V. Schally
HORMONE AND METABOLIC RESEARCH (2008)
Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting
Renzo Cescato et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Synthesis, characterization, and metabolic stability of porphyrin-peptide conjugates bearing bifunctional signaling sequences
Martha Sibrian-Vazquez et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Enhancement of somatostatin-receptor-targeted 177Lu-[DOTA0-Tyr3]- octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation
Tapan K. Nayak et al.
NUCLEAR MEDICINE AND BIOLOGY (2008)
Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors
Yoshinobu Shiose et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2007)
Targeted proapoptotic anticancer drug delivery system
Pooja Chandna et al.
MOLECULAR PHARMACEUTICS (2007)
Structure-activity study on the LH- and FSH-releasing and anticancer effects of gonadotropin-releasing hormone (GnRH)-III analogs
Magdolna Kovacs et al.
PEPTIDES (2007)
Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo
Stefanie Fister et al.
CANCER RESEARCH (2007)
A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, αVβ2/αVβ5 and MMP-2/-9
Li-Chun Sun et al.
CANCER LETTERS (2007)
Somatostatin-receptor-targeted α-emitting 213Bi is therapeutically more effective than β-emitting 177Lu in human pancreatic adenocarcinoma cells
Tapan K. Nayak et al.
NUCLEAR MEDICINE AND BIOLOGY (2007)
Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone
Joerg B. Engel et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2007)
Intracellular gonadotropin-releasing hormone receptors in breast cancer and gonadotrope lineage cells
Kathleen R. Sedgley et al.
JOURNAL OF ENDOCRINOLOGY (2006)
Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
Mihaela Ginj et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Imaging of neuroendocrine tumors
Vittoria Rufini et al.
SEMINARS IN NUCLEAR MEDICINE (2006)
Novel polymeric prodrug with multivalent components for cancer therapy
Jayant J. Khandare et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Gonadotropin-releasing hormone (GnRH) receptors in tumors: a new rationale for the therapeutical application of GnRH analogs in cancer patients?
M. Montagnani Marelli et al.
CURRENT CANCER DRUG TARGETS (2006)
Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy
S Koukouraki et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2006)
Arrestin-mediated ERK activation by gonadotropin-releasing hormone receptors - Receptor-specific activation mechanisms and compartmentalization
CJ Caunt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors
Terry W. Moody et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers
A Nagy et al.
BIOLOGY OF REPRODUCTION (2005)
Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1
JB Engel et al.
CANCER (2005)
Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide
SS Dharap et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Camptothecin-somatostatin conjugates inhibit the growth of small cell lung cancer cells
TW Moody et al.
PEPTIDES (2005)
Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207
G Keller et al.
EUROPEAN JOURNAL OF CANCER (2005)
Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues
G Keller et al.
CLINICAL CANCER RESEARCH (2005)
Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue
G Keller et al.
CANCER RESEARCH (2005)
Study of inhibitory effects of an antiangiogenic somatostatin-camptothecin conjugate on laser-induced choroidal neovascularization in rats
Yanno Bezerra et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2005)
Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell tines independent of multidrug resistance-1 (MDR-1) system
AR Günthert et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2004)
Chemotherapy targeted to cancers through tumoral hormone receptors
AV Schally et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2004)
Synthesis of peptide conjugated chelator oligomers for endoradiotherapy and MRT imaging
W Mier et al.
TETRAHEDRON LETTERS (2004)
Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor
C Gründker et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Conjugation of the closo-borane mereaptoundecahydrododecaborate (BSH) to a tumour selective peptide
W Mier et al.
ZEITSCHRIFT FUR ANORGANISCHE UND ALLGEMEINE CHEMIE (2004)
Effects of camptothecin conjugated to a somatostatin analog vector on growth of tumor cell lines in culture and related tumors in rodents
LC Sun et al.
DRUG DELIVERY (2004)
Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells
TW Moody et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Backbone metal cyclization:: novel 99mTc labeled GnRH analog as potential SPECT molecular imaging agent in cancer
Y Barda et al.
NUCLEAR MEDICINE AND BIOLOGY (2004)
Receptor-mediated targeting of a photosensitizer by its conjugation to gonadotropin-releasing hormone analogues
S Rahimipour et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides
SS Dharap et al.
JOURNAL OF CONTROLLED RELEASE (2003)
Peptide receptors as molecular targets for cancer diagnosis and therapy
JC Reubi
ENDOCRINE REVIEWS (2003)
Targeted proapoptotic LHRH-BH3 peptide
SS Dharap et al.
PHARMACEUTICAL RESEARCH (2003)
New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin
AV Schally et al.
LIFE SCIENCES (2003)
An a ustable release rate linking strategy for cytotoxin-peptide conjugates
JA Fuselier et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
HPMA copolymers with pH-controlled release of doxorubicin -: In vitro cytotoxicity and in vivo antitumor activity
K Ulbrich et al.
JOURNAL OF CONTROLLED RELEASE (2003)
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion:: a phase I study
L Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH): A new approach to targeted chemotherapy
A Nagy et al.
DRUGS OF THE FUTURE (2002)
Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide
Y Menda et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
M de Jong et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
Hypothalamic hormones and cancer
AV Schally et al.
FRONTIERS IN NEUROENDOCRINOLOGY (2001)
A novel mammalian receptor for the evolutionarily conserved type II GnRH
R Millar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates
JD Neill et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice
H Kiaris et al.
EUROPEAN JOURNAL OF CANCER (2001)
Somatostatin, its receptors and analogs, in lung cancer
KJ O'Byrne et al.
CHEMOTHERAPY (2001)
Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis
CM Huang et al.
CHEMISTRY & BIOLOGY (2000)
Immunotoxicity of ethyl carbamate in female BALB/c mice: role of esterase and cytochrome P450
SW Cha et al.
TOXICOLOGY LETTERS (2000)
Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro:: Implications for the design of preclinical studies
A Nagy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
JC Reubi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2000)
Value of peptide receptor scintigraphy using I-123-vasoactive intestinal peptide and In-111-DTPA-D-Phe(1)-octreotide in 194 carcinoid patients: Vienna university experience, 1993 to 1998
M Raderer et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
